Glucopet (Fludeoxyglucose (18f))

Glucopet is indicated for PET imaging procedures that require visualization of glucose metabolism. It helps clinicians evaluate disease presence and activity in several clinical settings.

• Oncologic PET imaging to detect and stage malignant tumors.
• Cardiac PET imaging for assessment of myocardial viability and perfusion.
• Neurological PET imaging to investigate epilepsy, dementia, and brain metabolism disorders.
• Whole‑body PET scans for metastatic disease evaluation.
• Research applications involving metabolic pathway studies.

Adverse reactions to Glucopet are generally mild but can include both common and serious events.

Common

• Transient flushing or warmth at the injection site.
• Mild nausea or vomiting.
• Short‑duration headache.
• Temporary dizziness or light‑headedness.

Serious

• Severe allergic reaction (anaphylaxis) with rash, bronchospasm, or hypotension.
• Significant radiation‑induced tissue injury in rare cases.

Glucopet should be used with careful consideration of patient‑specific factors and procedural requirements.

• Verify patient identity and confirm indication before administration.
• Assess for known hypersensitivity to radiopharmaceuticals or any component of the formulation.
• Use the lowest effective radioactive dose consistent with diagnostic quality.
• Pregnant or breastfeeding patients should only receive Glucopet when the potential benefit outweighs the risk.
• Ensure proper radiation safety measures for staff and environment.
• Review recent imaging studies to avoid unnecessary repeat exposure.

Glucopet may interact with other agents that affect glucose metabolism or radiation exposure.

Avoid

• Concurrent administration of high‑dose glucose or insulin that could alter tracer uptake.
• Use of other radiopharmaceuticals within a short interval that may cause cumulative radiation dose.

Use with caution

• Medications that significantly modify blood glucose levels (e.g., corticosteroids, antidiabetic drugs).
• Contrast agents used in CT that may affect PET/CT image interpretation.
• Chemotherapeutic agents that influence tumor metabolism.
• Substances that affect renal clearance, potentially altering tracer distribution.